Full text is available at the source.
Abstract
GIP receptor (GIPR) mRNA was consistently detected across all donors, while GLP-1 receptor (GLP-1R) mRNA was undetectable in skeletal muscle myoblasts from older adults with obesity.
- Neither semaglutide nor GIP treatment altered atrophy-related gene expression or the secretome, with no significant protein changes observed.
- Semaglutide reduced glycolytic and total ATP production rates and decreased lactate secretion, indicating a possible suppression of glycolytic activity.
- Myotube thickness and differentiation were not impaired by either treatment, with GIP increasing myotube thickness after 8 days.
- Direct stimulation of GLP-1 and GIP receptors did not produce major effects on atrophy, inflammation, morphology, myogenesis, or mitochondrial function in primary human skeletal muscle myotubes.
- Findings suggest that the lean mass loss associated with incretin-based therapies may result from indirect mechanisms rather than direct pharmacological effects.
Simplified